Meta10-BCMA CAR-T
Relapsed/Refractory Plasma Cell Neoplasms
Phase 1Active (Investigator-Initiated Trial)
Key Facts
Indication
Relapsed/Refractory Plasma Cell Neoplasms
Phase
Phase 1
Status
Active (Investigator-Initiated Trial)
Company
About Leman Biotech
AI-enabled metabolic cancer immunotherapy company developing next-generation metabolically armored cell therapies to cure solid tumors and hematological cancers.
View full company profile